Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Medical Biochemistry And Metabolomics
  9. Medical Biochemistry - Inorganic Elements And Compounds
  11. Effect Of Eltrombopag On Biochemical Assay Parameters.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Medical Biochemistry And Metabolomics
  9. Medical Biochemistry - Inorganic Elements And Compounds
  11. Effect Of Eltrombopag On Biochemical Assay Parameters.

Related Experiment Video

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.7K

Effect of eltrombopag on biochemical assay parameters.

Keiichi Nakano1, Masanori Seimiya2, Kazushige Kojima3

  • 1Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan.

Journal of Pharmaceutical and Biomedical Analysis
|June 13, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Eltrombopag causes yellowish-brown serum discoloration, interfering with biochemical tests. This study quantifies eltrombopag interference in total bilirubin and uric acid measurements, crucial for clinical labs.

Keywords:
BilirubinEltrombopagInterferenceLipemia index

More Related Videos

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

8.8K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.0K

Related Experiment Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.7K
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

8.8K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.0K

Area of Science:

  • Clinical Chemistry
  • Pharmacology
  • Biochemistry

Background:

  • Eltrombopag, a treatment for thrombocytopenia, is known to cause serum discoloration.
  • The precise extent and mechanisms of eltrombopag's interference with biochemical assays remain incompletely understood.
  • Limited data exists on eltrombopag's impact on enzymatic bilirubin assays, prevalent in Japan.

Purpose of the Study:

  • To investigate and quantify the interference of eltrombopag in biochemical parameter measurements.
  • To evaluate the effect of eltrombopag on total bilirubin (TB) levels using enzymatic, vanadate, and Doumas methods.
  • To assess eltrombopag's impact on other biochemical parameters, including uric acid.

Main Methods:

  • Serum samples from 17 eltrombopag-treated patients were analyzed.
Uric acid
  • Eltrombopag was added to drug-free serum to achieve concentrations from 2.5 to 40.0 µg/mL.
  • Spectrophotometric analysis, lipemia index, and 21 biochemical parameters including TB and uric acid were measured.

    • Main Results:

    • Eltrombopag induced concentration-dependent yellowish-brown serum discoloration and increased absorbance (340-640 nm).
    • Lipemia index significantly increased with eltrombopag concentration.
    • Total bilirubin measurements showed significant positive bias (enzymatic: 280.2%, vanadate: 124.6%, Doumas: 323.9% at 40.0 µg/mL).
    • Uric acid levels exhibited a significant, concentration-dependent negative bias.

    Conclusions:

    • Eltrombopag significantly interferes with TB measurements across multiple methods, particularly enzymatic assays.
    • The drug also causes a concentration-dependent negative bias in uric acid measurements.
    • Understanding these interferences is vital for accurate clinical laboratory result interpretation in patients receiving eltrombopag.